In a bid to strengthen its pipeline, Gilead has agreed to a multi-year collaboration with Goldfinch Bio to discover, develop and commercialise a pipeline of therapeutics for diabetic kidney disease (DKD) and certain orphan kidney diseases using Goldfinch’s genetic and biologic platforms. Gilead was developing its non-alcoholic steatohepatitis drug, selonsertib, for DKD but development was halted at Phase II due to a lack of efficacy.